The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway

Atherosclerosis

Volumn 228, Issue 1, 2013, Pages 18-28

  Catapano, A L ^a,b   Papadopoulos, N ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Cardiovascular; Hypercholesterolaemia; Monoclonal antibodies; PCSK9; Safety

Indexed keywords

1B20; ABCIXIMAB; ADALIMUMAB; ALIROCUMAB; AMG 145; ANTIBODY; ATORVASTATIN; BELIMUMAB; CANAKINUMAB; CETUXIMAB; DACLIZUMAB; DENOSUMAB; EZETIMIBE; GOLIMUMAB; INFLIXIMAB; IPILIMUMAB; LGT 209; MONOCLONAL ANTIBODY; MPSK 3169 A; OFATUMUMAB; OMALIZUMAB; PANITUMUMAB; PF 04950615; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; RAXIBACUMAB; RITUXIMAB; RN 316; SERINE PROTEINASE; UNCLASSIFIED DRUG; USTEKINUMAB;

ABDOMINAL PAIN; ADD ON THERAPY; ANKYLOSING SPONDYLITIS; ANTHRAX; ANTIBODY PRODUCTION; ANTIBODY TITER; ASTHMA; BINDING AFFINITY; BLEEDING; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC LEUKOCYTOCLASTIC VASCULITIS; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; COLORECTAL CANCER; CROHN DISEASE; CYTOKINE RELEASE SYNDROME; CYTOTOXICITY; DEMYELINATING DISEASE; DOSE RESPONSE; DRUG BINDING; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; FEVER; GAIN OF FUNCTION MUTATION; GENETIC ENGINEERING; HEAD AND NECK CANCER; HEART FAILURE; HEMATOMA; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; INJECTION SITE SWELLING; LEUKOCYTOCLASTIC VASCULITIS; LOSS OF FUNCTION MUTATION; LUPUS LIKE SYNDROME; LYMPHOMA; METASTATIC MELANOMA; MONOTHERAPY; MUCKLE WELLS SYNDROME; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; MYALGIA; NEPHRITIS; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIATIC ARTHRITIS; RECTUM HEMORRHAGE; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THYROID DISEASE; TUMOR LYSIS SYNDROME; VASCULITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; CARDIOVASCULAR DISEASES; HUMANS; HYPERCHOLESTEROLEMIA; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84876801739     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.01.044     Document Type: Review

References (135)

1. Cardiovascular diseases September 2011, World Health Organization, Available at:, [accessed 02.03.11]. http://www.who.int/mediacentre/factsheets/fs317/en/index.html.
2. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
3. Stamler J., Wentworth D., Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986, 256:2823-2828.
4. Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
5. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002, 106:3143-3421.
6. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl. 2):S1-S113.
7. Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
8. LaRosa J.C., Deedwania P.C., Shepherd J., et al. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol 2010, 105:283-287.
9. Wiviott S.D., Mohanavelu S., Raichlen J.S., Cain V.A., Nissen S.E., Libby P. Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study). Am J Cardiol 2009, 104:29-35.
10. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
11. Hsia J., MacFadyen J.G., Monyak J., Ridker P.M. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011, 57:1666-1675.
12. Ford E.S., Li C., Pearson W.S., Zhao G., Mokdad A.H. Trends in hypercholesterolemia, treatment and control among United States adults. Int J Cardiol 2010, 140:226-235.
13. Waters D.D., Brotons C., Chiang C.W., et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009, 120:28-34.
14. Kotseva K., Wood D., De Backer G., De Bacquer D., Pyorala K., Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009, 16:121-137.
15. Pijlman A.H., Huijgen R., Verhagen S.N., et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010, 209:189-194.
16. The diabetes dilemma for statin users March 2012, New York Times, Available at:, [accessed 28.11.12]. http://www.nytimes.com/2012/03/05/opinion/the-diabetes-dilemma-for-statin-users.html.
17. Bruckert E., Hayem G., Dejager S., Yau C., Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403-414.
18. Hansel T.T., Kropshofer H., Singer T., Mitchell J.A., George A.J. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010, 9:325-338.
19. Nelson A.L., Dhimolea E., Reichert J.M. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010, 9:767-774.
20. Coles A.J., Compston D.A., Selmaj K.W., et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008, 359:1786-1801.
21. Drewe E., Powell R.J. Clinically useful monoclonal antibodies in treatment. J Clin Pathol 2002, 55:81-85.
22. Foroughi S., Foster B., Kim N., et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 2007, 120:594-601.
23. Gerber D.E. Targeted therapies: a new generation of cancer treatments. Am Fam Physician 2008, 77:311-319.
24. Newsome B.W., Ernstoff M.S. The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?. Br J Clin Pharmacol 2008, 66:6-19.
25. Tamhane U.U., Gurm H.S. The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice. Expert Opin Drug Saf 2008, 7:809-819.
26. Therapeutic monoclonal antibodies approved or in review in the European Union or United States February 2012, The Antibody Society, Available at:, [accessed 08.05.12]. http://www.antibodysociety.org/news/approved_mabs.php.
27. Presta L.G. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008, 20:460-470.
28. Rodriguez I., Erdman A., Padhi D., et al. Electrocardiographic assessment for therapeutic proteins-scientific discussion. Am Heart J 2010, 160:627-634.
29. Singh J.A., Wells G.A., Christensen R., et al. Adverse effects of biologics: a network meta-analysis and cochrane overview. Cochrane database of systematic reviews. Cochrane Database Syst Rev 2011, 2:CD008794.
30. Tabrizi M.A., Roskos L.K. Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today 2007, 12:540-547.
31. Salvana E.M., Salata R.A. Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 2009, 22:274-290.
32. Niebecker R., Kloft C. Safety of therapeutic monoclonal antibodies. Curr Drug Saf 2010, 5:275-286.
33. Maggi E., Vultaggio A., Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 2011, 7:55-63.
34. Bruhns P., Iannascoli B., England P., et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009, 113:3716-3725.
35. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use November 2010, European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), Available at:, [accessed 08.05.12]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/11/WC500099362.pdf.
36. Chapman K., Pullen N., Coney L., et al. Preclinical development of monoclonal antibodies: considerations for the use of non-human primates. MAbs 2009, 1:505-516.
37. Horton J.D., Cohen J.C., Hobbs H.H. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 2007, 32:71-77.
38. Tibolla G., Norata G.D., Artali R., Meneghetti F., Catapano A.L. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis 2011, 21:835-843.
39. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
40. Sgro C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology 1995, 105:23-29.
41. Stern M., Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 2005, 54:11-29.
42. Gardam M.A., Keystone E.C., Menzies R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003, 3:148-155.
43. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005, 31:456-473.
44. Buggage R.R., Levy-Clarke G., Sen H.N., et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease. Ocul Immunol Inflamm 2007, 15:63-70.
45. Reff M.E., Hariharan K., Braslawsky G. Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control 2002, 9:152-166.
46. Presta L.G., Lahr S.J., Shields R.L., et al. Humanization of an antibody directed against IgE. J Immunol 1993, 151:2623-2632.
47. Janeway C.A. Immunobiology: the immune system in health and disease 2005, Churchill Livingston/Garland Science, New York, NY. 6th ed.
48. Carmen S., Jermutus L. Concepts in antibody phage display. Brief Funct Genomic Proteomic 2002, 1:189-203.
49. ® increases the speed and efficiency of fully human therapeutic monoclonal antibody development. Regeneron is using this technology to produce the next generation of drug candidates 2011, Regeneron, Available at:, [accessed 05.04.12]. http://www.regeneron.com/velocimmune.
50. Lonberg N., Huszar D. Human antibodies from transgenic mice. Int Rev Immunol 1995, 13:65-93.
51. Jakobovits A. The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice. Expert Opin Investig Drugs 1998, 7:607-614.
52. Humira [Summary of product characteristics] 2012, Abbott Laboratories, North Chicago, IL.
53. Vectibix [Summary of product characteristics] 2012, Amgen Inc, Thousand Oaks, CA.
54. SIMPONI [Summary of product characteristics] 2012, Centocor, Horsham, PA.
55. Ilaris [Summary of product characteristics] 2012, Novartis, Basel, Switzerland.
56. Stelara [Summary of product characteristics] 2012, Janssen Biotech Inc, Horsham, PA.
57. Arzerra [Summary of product characteristics] 2012, GlaxoSmithKline, Brentford, Middlesex.
58. Prolia [Summary of product characteristics] 2012, Amgen, Thousand Oaks, CA.
59. Benlysta [Summary of product characteristics] 2012, Human Genome Sciences, Rockville, MD.
60. Yervoy [Summary of product characteristics] 2012, Bristol-Myers Squibb, New York, NY.
61. Commins S.P., Platts-Mills T.A. Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant. J Allergy Clin Immunol 2009, 124:652-657.
62. Nishimoto N., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009, 68:1580-1584.
63. Mease P.J., Ory P., Sharp J.T., et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). Ann Rheum Dis 2009, 68:702-709.
64. Weinblatt M.E., Keystone E.C., Furst D.E., Kavanaugh A.F., Chartash E.K., Segurado O.G. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006, 65:753-759.
65. Colombel J.F., Loftus E.V., Tremaine W.J., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004, 126:19-31.
66. Covelli M., Sarzi-Puttini P., Atzeni F., Macchioni P. Safety of rituximab in rheumatoid arthritis. Reumatismo 2010, 62:101-106.
67. Aster R.H., Bougie D.W. Drug-induced immune thrombocytopenia. N Engl J Med 2007, 357:580-587.
68. Curtis B.R., Swyers J., Divgi A., McFarland J.G., Aster R.H. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002, 99:2054-2059.
69. Mongey A.B., Hess E.V. Drug insight: autoimmune effects of medications-what's new?. Nat Clin Pract Rheumatol 2008, 4:136-144.
70. Vogel W.H. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs 2010, 14:E10-E21.
71. Askling J., Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20:334-339.
72. Chien K.R. Herceptin and the heart-a molecular modifier of cardiac failure. N Engl J Med 2006, 354:789-790.
73. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820-7826.
74. Osterholm M.T. Preparing for the next pandemic. N Engl J Med 2005, 352:1839-1842.
75. Gurm H.S., Tamhane U., Meier P., Grossman P.M., Chetcuti S., Bates E.R. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. Circ Cardiovasc Interv 2009, 2:230-236.
76. Tcheng J.E., Kandzari D.E., Grines C.L., et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2003, 108:1316-1323.
77. Geeganage C., Wilcox R., Bath P.M. Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis. BMC Med 2010, 8:36.
78. Dietschy J.M., Turley S.D., Spady D.K. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993, 34:1637-1659.
79. Goldstein J.L., Anderson R.G.W., Brown M.S. Receptor-mediated endocytosis and the cellular uptake of low density lipoprotein. Membrane recycling 1982, Pitman Books, London, p. 77-95.
80. Duff C.J., Hooper N.M. PCSK9: an emerging target for treatment of hypercholesterolemia. Expert Opin Ther Targets 2011, 15:157-168.
81. Li J., Tumanut C., Gavigan J.A., et al. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem J 2007, 406:203-207.
82. Poirier S., Mayer G., Poupon V., et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem 2009, 284:28856-28864.
83. Farnier M. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications. Am J Cardiovasc Drugs 2011, 11:145-152.
84. Seidah N.G. PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets 2009, 13:19-28.
85. Zhang D.W., Lagace T.A., Garuti R., et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007, 282:18602-18612.
86. McNutt M.C., Lagace T.A., Horton J.D. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem 2007, 282:20799-20803.
87. Multiple ascending dose study of SPC5001 in treatment of healthy subjects and subjects with FH November 2012, Available at:, [accessed 05.04.12]. http://clinicaltrials.gov/ct2/show/NCT01350960%3fterm%3dNCT01350960%26rank%3d1.
88. Safety study of BMS-844421 for treatment of hypercholesterolemia January 2011, Available at:, [accessed 05.04.12]. http://clinicaltrials.gov/ct2/show/NCT01082562%3fterm%3dNCT01082562%26rank%3d1.
89. Trial to evaluate safety and tolerability of ALN-PCS02 in subjects with elevated LDL-cholesterol (LDL-C) March 2012, Available at:, [accessed 05.04.12]. http://clinicaltrials.gov/ct2/show/NCT01437059%3fterm%3dNCT01437059%26rank%3d1.
90. McKenney J.M., Koren M.J., Kereiakes D.J., Hanotin C., Ferrand A.-C., Stein E.A. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin Type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy (NCT01288443). J Am Coll Cardiol 2012, 59:2344-2353.
91. Stein E.A., Gipe D., Bergeron J., et al. Effects of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce LDL cholesterol in patients with heterozygous familial hypercholesterolemia on stable statin dose with or without ezetimibe therapy (NCT:01266876). Lancet 2012, 380:29-36.
92. Roth E.M., McKenney J.M., Hanotin C., Asset G., Stein E.A. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012, 367:1891-1900.
93. Giugliano R.P., Desai N.R., Kohli P., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012, 380:2007-2017. 10.1016/S0140-6736(12)61770-X.
94. Koren M.J., Scott R., Kim J.B., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012, 380:1995-2006. 10.1016/S0140-6736(12)61771-1.
95. Raal F., Scott R., Somaratne R., et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012, 126:2408-2417.
96. Sullivan D., Olsson A.G., Scott R., et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012, 308:2497-2506.
97. Zhang L., McCabe T., Condra J.H., et al. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci 2012, 8:310-327.
98. A phase II study of the safety and efficacy of MPSK3169A in patients with coronary heart disease or high risk of coronary heart disease 2012, [accessed 02.08.12]. http://clinicaltrials.gov/ct/show/NCT01609140.
99. Davignon J., Dubuc G., Seidah N.G. The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr Atheroscler Rep 2010, 12:308-315.
100. Abifadel M., Varret M., Rabes J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
101. Naoumova R.P., Tosi I., Patel D., et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 2005, 25:2654-2660.
102. Norata G.D., Garlaschelli K., Grigore L., et al. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis 2010, 208:177-182.
103. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264-1272.
104. Zhao Z., Tuakli-Wosornu Y., Lagace T.A., et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006, 79:514-523.
105. Allard D., Amsellem S., Abifadel M., et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat 2005, 26:497.
106. Cohen J., Pertsemlidis A., Kotowski I.K., Graham R., Garcia C.K., Hobbs H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005, 37:161-165.
107. Benn M., Nordestgaard B.G., Grande P., Schnohr P., Tybjaerg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010, 55:2833-2842.
108. Folsom A.R., Peacock J.M., Boerwinkle E. Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease. Atherosclerosis 2009, 202:211-215.
109. Cariou B., Ouguerram K., Zair Y., et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2009, 29:2191-2197.
110. Hooper A.J., Marais A.D., Tanyanyiwa D.M., Burnett J.R. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007, 193:445-448.
111. Rashid S., Curtis D.E., Garuti R., et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc Natl Acad Sci U S A 2005, 102:5374-5379.
112. Alborn W.E., Cao G., Careskey H.E., et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007, 53:1814-1819.
113. Lambert G., Ancellin N., Charlton F., et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008, 54:1038-1045.
114. Huijgen R., Fouchier S.W., Denoun M., et al. Plasma levels of proprotein convertase subtilisin kexin type 9 (PCSK9) and phenotypic variability in familial hypercholesterolemia. J Lipid Res 2012, 53:979-983.
115. Chan J.C., Piper D.E., Cao Q., et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A 2009, 106:9820-9825.
116. Gusarova V, Howard VG, Okamoto H, et al. Reduction of LDL cholesterol by a monoclonal antibody to PCSK9 in rodents and nonhuman primates. Clin Lipidol 2012.
117. Liang H., Chaparro-Riggers J., Strop P., et al. Proprotein convertase subtilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther 2012, 340:228-236.
118. Chaparro-Riggers J., Liang H., Devay R.M., et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering an antibody with pH-sensitive binding to PCSK9. J Biol Chem 2012, 287:11090-11097.
119. Ni Y.G., Di M.S., Condra J.H., et al. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res 2011, 52:78-86.
120. Ni Y.G., Condra J.H., Orsatti L., et al. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J Biol Chem 2010, 285:12882-12891.
121. Schaefer H., Falk E., Herling A.W., Schwahn U., Sleeman M.W., Rutten H. Cholesterol lowering effect of SAR236553/REGN727 in hamster after single s.c. injection. Drugs affecting lipid metabolism XVII international symposium - diabetes, obesity and the metabolic syndrome March 14-16, 2011, Qatar, Doha.
122. Abifadel M., Pakradouni J., Collin M., et al. Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. Expert Opin Ther Pat 2010, 20:1547-1571.
123. Chan D.C. Regulation of proprotein convertase subtilisin/kexin type 9: therapeutical perspectives. Atherosclerosis 2011, 217:77-79.
124. Stein E.A., Mellis S., Yancopoulos G.D., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012, 366:1108-1118.
125. Dias C.S., Shaywitz A.J., Wasserman S.M., et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012, 60:1888-1898.
126. Steinberg D., Witztum J.L. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci U S A 2009, 106:9546-9547.
127. Carlson J.A., Cavaliere L.F., Grant-Kels J.M. Cutaneous vasculitis: diagnosis and management. Clin Dermatol 2006, 24:414-429.
128. Garcia-Porrua C., Gonzalez-Gay M.A., Lopez-Lazaro L. Drug associated cutaneous vasculitis in adults in northwestern Spain. J Rheumatol 1999, 26:1942-1944.
129. Ramos-Casals M., Brito-Zeron P., Munoz S., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Med (Baltimore) 2007, 86:242-251.
130. A multiple dose study of PF-04950615 (RN316) in subjects on maximum doses of statins 2012, [accessed 03.09.12]. http://clinicaltrials.gov/ct/show/NCT01350141.
131. Sanofi and Regeneron launch comprehensive phase 3 clinical program with LDL-cholesterol-lowering PCSK9 antibody 2012, Sanofi website, Available at:, [accessed 28.11.12]. http://en.sanofi.com/Images/30757_20120720_PCSK9_en.pdf.
132. Efficacy and safety of SAR236553 (REGN727) versus placebo on top of lipid-modifying therapy in patients with high cardiovascular risk and hypercholesterolemia 2012, [accessed 28.11.12]. http://clinicaltrials.gov/ct2/show/NCT016441754.
133. Study of REGN727 (SAR236553) in patients with primary hypercholesterolemia and moderate, high, or very high cardiovascular (CV) risk, who are intolerant to statins (Odyssey Alternative) 2012, [accessed 28.11.12]. http://clinicaltrials.gov/ct2/show/NCT01709513.
134. Efficacy and safety of SAR236553 (REGN727) versus placebo on top of lipid-modifying therapy in patients with heterozygous familial hypercholesterolemia (ODYSSEY High FH) 2012, [accessed 28.11.12]. http://clinicaltrials.gov/ct2/show/NCT016176557.
135. Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with SAR236553 (REGN727) (ODYSSEY Outcomes) 2012, [accessed 28.11.12]. http://clinicaltrials.gov/ct2/show/NCT01663402.